QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

/PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS)...

Related Keywords

United Kingdom ,Germany ,Cambridge ,Cambridgeshire ,Netherlands ,Belgium ,Canada ,Ireland ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Angela Genge ,Kasper Roet ,Kevin Eggan ,Healthcare Products Regulatory Agency ,European Union ,Eggan Lab ,European Network To Cure ,Prnewswire Quralis Corporation ,Alis Corporation ,Clinical Trial Application ,Therapeutic Section ,European Network ,Trial Authorisation ,Quralis ,